JDP Therapeutics, Inc. Announces Appointment of Joshua M. Tarnoff to CEO

JDP Therapeutics, Inc. Announces Appointment of Joshua M. Tarnoff to CEO

LANSDALE, PENNSYLVANIA, USA, January 4, 2010 - JDP Therapeutics, Inc, a specialty pharmaceutical company, announced today the appointment of Joshua M. Tarnoff to the position of Chief Executive Officer and Executive Director to the company's Board of Directors.

Mr. Tarnoff brings to the company over 25 years of pharmaceutical and biotechnology experience. His most recent positions include CEO at Houston Pharma, Inc. (and its subsidiary Potomac Pharma, Inc.), CCO at ViroPharma, Inc., and led a $1.5 billion U.S. business unit for AstraZeneca. Mr. Tarnoff has held a number of roles in executive management and progressively responsible positions in corporate development and commercially based positions across a wide variety of therapeutic areas in both the hospital and primary care settings.

JDP Therapeutics' founder and President, Jie Du, Ph.D. commented "We are very excited to have Josh join our team. He comes to us with a proven track record and long list of achievements in operations and corporate development and the leadership skills that will take the company to the next level as we begin our formal clinical development programs."

JDP Therapeutics Inc., founded in 2008, is a specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

For further information, please call 215-661-8557 or email [email protected]

Suggested Articles

In a pandemic world, the biotech funding environment couldn’t look brighter, and today Pfizer shone its own light.

Gilead is tapping long-term Stanford University researcher Mark Genovese, M.D., to lead its NASH, fibrosis and arthritis pipeline programs.

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…